Editas Medicine, Inc. (EDIT) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
EDIT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
EDIT Revenue Analysis (2013–2024)
As of March 2, 2026, Editas Medicine, Inc. (EDIT) generated trailing twelve-month (TTM) revenue of $46.4 million, reflecting explosive growth of +12265.6% year-over-year. The most recent quarter (Q3 2025) recorded $7.5 million in revenue, up 110.8% sequentially.
Looking at the longer-term picture, EDIT's 5-year compound annual growth rate (CAGR) stands at +9.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $90.7 million in 2020.
Revenue diversification analysis shows EDIT's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), EDIT has outperformed the peer group in terms of revenue growth. Compare EDIT vs ALNY →
Peer Comparison
Compare EDIT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EDITCurrent | $46M | +12265.6% | +9.5% | -777.2% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $32.3M | -58.6% | $32.3M | 100.0% | $-251,152,000 | -777.2% |
| 2023 | $78.1M | +296.3% | $72.1M | 92.2% | $-169,181,000 | -216.6% |
| 2022 | $19.7M | -22.8% | $13.4M | 67.9% | $-225,950,000 | -1146.3% |
| 2021 | $25.5M | -71.8% | $20.5M | 80.2% | $-193,146,000 | -756.1% |
| 2020 | $90.7M | +341.9% | $-67,264,000 | -74.1% | $-134,840,000 | -148.6% |
| 2019 | $20.5M | -35.7% | $-76,367,000 | -372.0% | $-140,922,000 | -686.4% |
| 2018 | $31.9M | +132.6% | $-58,717,000 | -183.9% | $-113,727,000 | -356.1% |
| 2017 | $13.7M | +126.8% | $-69,431,000 | -505.8% | $-119,933,000 | -873.6% |
| 2016 | $6.1M | +271.6% | $-50,926,000 | -841.3% | $-97,188,000 | -1605.6% |
| 2015 | $1.6M | - | $-17,217,000 | -1056.9% | $-35,312,000 | -2167.7% |
See EDIT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EDIT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EDIT vs AGIO
See how EDIT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is EDIT's revenue growth accelerating or slowing?
EDIT revenue is accelerating at +12265.6% year-over-year, exceeding the 5-year CAGR of +9.5%. TTM revenue reached $46M. Growth momentum has increased versus prior periods.
What is EDIT's long-term revenue growth rate?
Editas Medicine, Inc.'s 5-year revenue CAGR of +9.5% reflects the sustained expansion pattern. Current YoY growth of +12265.6% is above this long-term average.
How is EDIT's revenue distributed by segment?
EDIT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.